http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2375082-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bf82b2c04febd9f5fc6ead8595272b9a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-36 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-557 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 |
| filingDate | 2006-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_230b08160c80fe23de9be8b04e01cc8e |
| publicationDate | 2012-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2375082-T3 |
| titleOfInvention | COMPOSITION FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM. |
| abstract | The use of an 11-deoxy-prostaglandin compound for the manufacture of a composition for the treatment of a central nervous system disorder in a mammalian subject, comprising an effective amount of an 11-deoxy-prostaglandin compound represented by the following formula (III): where L is hydrogen, hydroxy, halogen, linear or branched C1-C6 alkyl, linear or branched C1-C6 hydroxyalkyl, linear or branched C1-C6 alkanoyl or oxo, where the five-membered ring may have optionally at least one double bond; A is -CH3, -CH2OH -COCH2OH, -COOH or one of its salts, ethers, esters or amides; B is -CH2-CH2-; Z is where R4 and R5 are hydrogen, hydroxy, halogen, linear or branched C1-C6 alkyl, linear or branched C1-C6 alkoxy or linear or branched C1-C6 hydroxyalkyl, where R4 and R5 are not hydroxy and linear C1-C6 alkoxy or branched at the same time; X1 and X2 are halogens; R1 is a saturated or unsaturated linear or branched C1_c14 aliphatic hydrocarbon, which is not substituted or substituted by halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one of the carbon atoms in the aliphatic hydrocarbon is optionally substituted with oxygen, nitrogen or sulfur; R2 is a straight or branched C1-C6 alkylene or single bond; and R3 is linear or branched C1-C6 alkyl, linear or branched C1-C6 alkoxy, linear or branched (C1-C6) alkanoyl, C3-C6 cycloalkyl, (C3-C6) oxy, aryl, aryloxy, a heterocyclic group or a heterocyclic-oxy group, and at least one of the carbon atoms in the aliphatic hydrocarbon is optionally substituted with oxygen, nitrogen or sulfur. |
| priorityDate | 2005-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.